Few data exist in the literature regarding organ transplant recipients who are diagnosed with and treated for prostate cancer. We found excellent outcomes in transplant recipients who receive radiotherapy for prostate cancer. Background: Few data exist in the literature regarding outcomes of men with prostate cancer (CaP) who are receiving immunosuppression from prior organ transplantation. The aim of this study was to evaluate biochemical disease-free survival, distant metastasisefree survival, overall survival, and toxicity in patients with organ transplants who were later treated with definitive radiotherapy for CaP. Patients and Methods: Our institutional CaP registry was reviewed to identify patients who had undergone an organ transplantation before CaP diagnosis. Between 1999 and 2013, a total of 28 organ transplant recipients treated with definitive radiotherapy for CaP were identified. Treatment consisted of either I-125 low-dose-rate brachytherapy or external-beam radiotherapy. All patients were receiving immunosuppressive medications. Results: The median age was 66 years. Median follow-up time was 30 months. Twenty-four patients (86%) were treated with brachytherapy, and 4 patients (14%) were treated with external-beam radiotherapy. Nine patients (32%) had low-risk CaP, 14 (50%) had intermediate-risk CaP, and 5 (18%) had high-risk CaP. At the time of last follow-up, 2 patients had died, 1 from metastatic CaP and 1 from other causes. The 3-year biochemical disease-free survival was 95.8%. The 3-year distant metastasisefree survival was 93.1%. The 3-year overall survival was 93.8%. One patient developed grade 3 late gastrointestinal toxicity. Conclusion: This represents one of the largest reported series of outcomes in patients with organ transplantation and CaP. Organ transplant recipients treated with prostate radiotherapy have excellent 3-year outcomes.
Introduction
Organ transplant recipients have an increased incidence of malignancy. [1] [2] [3] Because of immunosuppression after transplantation, organ transplant recipients often have poorer disease-specific survival compared to the general population. 4, 5 Malignancies may behave more aggressively in previously transplanted patients compared to the immunocompetent population. This is thought to be a result of decreased immune surveillance of tumor cells under immunosuppression. 6 Furthermore, immunosuppressive therapy may play a role in carcinogenesis. 2 The impact of cancer after transplantation has increased with the improved life expectancy of transplant recipients, and cancer is now one of the most common causes of death 5 years after transplantation. 6 With improved life span of transplant recipients and better screening practices, prostate cancer (CaP) incidence has increased in this population. Genitourinary (GU) malignancies are the second most common malignancy in the renal transplantation population in the United States. 2 A French study demonstrated a standardized incidence ratio of 3.6 for CaP in patients who underwent renal transplantation. 7 An Italian study demonstrated a standardized incidence ratio of 1.7 for CaP in a cohort of kidney transplant recipients. 8 In contrast, a US series reported that the 5-year cumulative incidence for CaP was lower in transplant recipients compared to the general population, with a standardized incidence ratio of 0.92. 6 This difference is likely attributable to differences in screening practices between Europe and the United States, where routine prostate-specific antigen (PSA) screening is performed before transplantation.
Localized CaP can be treated with various options, including radical prostatectomy, external-beam radiotherapy (EBRT), and brachytherapy. These different treatment options have similar efficacy in the general population. 9 Because of this, treatment selection is largely based on the differing adverse effect profiles. Transplant recipients treated with radical prostatectomy have similar outcomes to the general immunocompetent population. 10 However, relatively little is known about outcomes with radiotherapy via either EBRT or brachytherapy. The purpose of this study was to report outcomes with regard to biochemical disease-free survival (BDFS), distant metastasisefree survival, overall survival (OS), and toxicity in a cohort of transplant recipients treated with radiotherapy.
Patients and Methods
After receipt of institutional review board approval, our institution-approved CaP registry was reviewed to identify patients who had undergone an organ transplantation before diagnosis of CaP. Between 1999 and 2013, a total of 28 organ transplant recipients treated with radiotherapy for CaP at a single tertiary-care institution were identified. Routine assessment included history and physical examination, digital rectal examination, serum PSA, and transrectal ultrasound-guided core needle biopsies of the prostate gland with histologic grading and Gleason score. Patients with distant or nodal metastatic disease, as identified by bone scan or computed tomographic scan of the abdomen and pelvis, were excluded from this study. Patient disease was clinically staged using the sixth edition of the American Joint Committee on Cancer, as recorded by the digital rectal examination. Magnetic resonance imaging was not used for staging. Treatment consisted of either brachytherapy or EBRT. Risk stratification was done using National Comprehensive Cancer Network criteria.
Brachytherapy was performed using I-125 low-dose-rate brachytherapy. A minimum dose of 144 Gy was prescribed to the periphery of the prostate. Intraoperative planning target volumes were determined by prostatic ultrasound the day of the implant. Provision of prophylactic antibiotics was no different than in patients who did not undergo transplantation; typically a fluoroquinolone or a cephalosporin was provided. Implants were performed using a transperineal approach with transrectal ultrasound guidance. Postimplant dosimetry was performed using a computed tomography scan with 3 mm slice thickness 4 weeks after implantation.
EBRT was performed with intensity-modulated radiotherapy. Treatment planning computed tomography images were obtained with the patient in the supine position. The clinical target volume included the prostate and seminal vesicles, and a planning target volume encompassed the clinical target volume with a margin of 4 to 10 mm. Radiation dose consisted of a hypofractionated regimen of 70 Gy in 28 fractions of 2.5 Gy per fraction, or a standard fractionation regimen of 78 Gy in 39 fractions of 2 Gy per fraction, both resulting in similar biologically equivalent doses. The choice of the fractionation scheme was made at the discretion of the treating physician. Daily image guidance prostate localization was used and consisted of the B-mode acquisition and targeting transabdominal ultrasound system. All high-risk patients received EBRT combined with concurrent androgen deprivation therapy for a median duration of 6 months (range, 6-15 months).
Overall, 13 patients had undergone kidney transplantation, 9 patients heart transplantation, 3 patients liver transplantation, 1 patient lung transplantation, 1 patient kidney and pancreas transplantation, and 1 patient liver and heart transplantation. All patients received immunosuppressive medications, which included cyclosporine (n ¼ 8), mycophenolate mofetil (n ¼ 13), azathioprine (n ¼ 3), tacrolimus (n ¼ 12), sirolimus (n ¼ 9), and/or prednisone (n ¼ 20).
Parameters examined included initial PSA values, Gleason score at initial biopsy, PSA nadir, PSA trends, BDFS, distant metastasisefree survival, and OS. Biochemical failure was defined using the American Society for Radiation Oncology definition of nadir plus 2 ng/mL. Toxicities were scored by Radiation Therapy Oncology Group (RTOG) criteria.
Results
The median age at the time of treatment for CaP was 66 years (range, 42-80 years). Median time from date of transplantation to diagnosis of CaP was 7.4 years (range, 0.6-40.4 years). Median follow-up time was 30 months (range, 1-129 months). Twenty-four patients (86%) were treated with prostate implant and 4 patients Table 2 . Sixteen patients (57%) developed grade 1 acute GU toxicity, and 5 patients (18%) developed grade 1 late GU toxicity. Four patients (14%) developed grade 2 acute GU toxicity, and 1 patient (4%) developed grade 2 late GU toxicity. No patients developed grade 3 or higher acute or late GU toxicity. No adverse infectious complications were noted. These results are summarized in Table 3 . Four patients (14%) developed grade 1 acute gastrointestinal (GI) toxicity, and 2 patients (7%) developed grade 1 late GI toxicity. Two patients (7%) developed grade 2 acute GI toxicity, and no patients developed grade 2 late GI toxicity. No patients developed grade 3 acute GI toxicity, and 1 patient (4%) developed grade 3 late GI toxicity. No patients developed grade 4 or higher acute or late GI toxicity. These results are summarized in Table 4 .
Discussion
An increased risk of malignancy after solid organ transplantation has been demonstrated in multiple series. 6, 11, 12 In the United
States, an incidence of > 4% has been reported for developing cancer over a 5-year period. 6 There is an increased risk for 32 different malignancies after solid organ transplants, with a standardized incidence ratio of 2.1. The most common malignancies with elevated risk after transplantation include non-Hodgkin lymphoma and cancers of the lung, liver, and kidney. This increased risk is likely attributable to several factors. Poor immune control of oncogenic viruses is thought to play a role in carcinogenesis. This is particularly true for the association of EpsteinBarr virus and the elevated risk of non-Hodgkin lymphoma in transplant recipients. 6 Furthermore, various immunosuppressive medications have been linked to the development of malignancy. Calcineurin inhibitors are associated with the development of posttrasnplantation malignancies. 13 The calcineurin inhibitor cyclosporine has been show in vitro to alter adenocarcinoma morphology, increase cell motility, and promote invasive growth through increased expression of exploratory pseudopodia. 14 Furthermore, cyclosporine promotes transcription and expression of transforming growth factor beta, which has been shown in experimental models of prostate adenocarcinoma in rats to promote tumor mobility, angiogenesis, and metastases. 15 Azathoprine has direct carcinogenic effect through DNA intercalation. 16 Newer transplant medications have been shown to have antiproliferative activity. Sirolimus, a mammalian target of rapamycin inhibitor, has been shown to inhibit prostate adenocarcinoma cells lines in vitro. 17, 18 Relatively little literature exists regarding CaP after solid organ transplantation. In a series of 62 patients, Kleinclauss et al 2 reported
early occurrence compared to the general population, with a median age at diagnosis of 63 years. This series also reported a high incidence of locally advanced disease and metastatic disease compared to the general population. 2 Konety et al 19 reported a series of 18 patients diagnosed with CaP after organ transplantation, with the majority undergoing radical prostatectomy for clinically localized disease; the overall cancer-specific death rate was 11% in the subset undergoing radical prostatectomy, which is comparable to what would be expected in the general population for localized disease. Of note, 3 patients received definitive EBRT, and the cancerspecific death rate was 0. Because of comparable outcomes to the general population, Konety et al recommended pursuing aggressive definitive treatment in patients with a history of organ transplantation. Similarly, a survey of French renal transplantation centers by Cormier et al 20 showed an early age at diagnosis of 63 years.
Seventeen men were treated definitively with radical prostatectomy, and after a mean follow-up of 18 months, 16 men were alive with no evidence of disease. This suggests that patients treated surgically for localized CaP after solid organ transplant have a similar favorable outcome compared to the general immunocompetent population. 21 and this may reflect a shorter follow-up period. These results are compared in Table 5 . Our 3-year BDFS is comparable to the general immunocompetent population after definitive radiotherapy for localized CaP, with ranges reported from 85% to 95%, including in comparison to patients across all risk groups treated at our own institution. 9, 22, 23 Toxicity from definitive radiotherapy was low and comparable to the general population. In a series of 525 patients treated with EBRT, brachytherapy, or radical prostatectomy, late GI and GU toxicity was evaluated. 24 Results showed the rate of RTOG grade 2 or higher GU toxicity from radiotherapy to be between 0.8% and 3.4%. Our series showed a rate of 4% of grade 2 or higher late GU toxicity, which is comparable to the immunocompetent population. Hunter et al 24 reported a grade 2 or higher late GI toxicity between 1.1% and 4.7%, and this is similar to our reported rate of 4%. Thus, despite patients receiving immunosuppressive medication with known potential GI toxicity, this did not increase the incidence of acute or late GI toxicity from radiotherapy. The strengths of our study include its large sample size compared to other series, and our inclusion of patients treated with both EBRT and brachytherapy. While other series report on outcomes after renal transplantation or renal or heart transplantation, this series also contains patients with lung, liver, and pancreas transplants. There has been recent interest in the literature on this topic, with most reported series consisting of surgically treated patients. 25, 26 Unfortunately, much of the radiotherapy literature consists of single case reports, so it is difficult to compare our series with other institutions. Nonetheless, our outcomes in transplant recipients appear to be favorable and comparable to outcomes in immunocompetent patients. As such, we offer definitive external radiotherapy or brachytherapy to properly selected CaP patients with an intent to cure.
Conclusion
We report what is to our knowledge the largest series of patients treated with definitive radiotherapy for CaP after receiving a solid organ transplant. Overall, patients have favorable BDFS that is similar to the immunocompetent population and acceptable toxicity that is comparable to the general population. Given these favorable outcomes, we recommend a curative-intent treatment approach for localized CaP in the setting of receipt of a previous solid organ transplant.
Clinical Practice Points
Organ transplant recipients are at risk of developing cancer while receiving immunosuppressive therapy. Patients with CaP are often treated with radiotherapy; however, it is unclear whether organ transplant recipients fare as well as nonimmunosuppressed patients. We found that radiotherapy, either EBRT or brachytherapy, can offer excellent outcomes in this group of patients.
